Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies
Open accessThe DOI matches its Crossref record; 238 of the 239 references it cites were found in a registry or an index.
Abstract
Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer’s disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ɛ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“has been shown in a wide range of studies to contribute significantly to the pathogenesis and progression of AD2,8–19.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading to dysfunction and loss of synapses and eventual neuronal death1,2.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD pathology occurs well before (up to two decades) the onset of clinical symptoms2–4.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by an accumulation of senile plaques (SP) [composed mostly of fibrillary amyloid beta-peptide (Aβ) and dystrophic neurites] and neurofibrillary tangles (NFT) [composed of hyperphosphorylated tau protein] in the brain”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research from our laboratories11,12,34 and many others2,4,8,10 has shown that inefficient glucose utilization (and thus impaired ATP production) and oxidative damage are intimately related.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–238 of 238
Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease
Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Porter, T., Ames, D., Fowler, C., Rainey-Smith, S., Snyder, P. J., Martins, R. N., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002604 · Cited by 37
Self-citationSojkova, J., & M. Resnick, S. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745375 · Cited by 36 · cited 1×
“The lack of a strong association between A deposition and measures of cognition, synaptic activity, and neurodegeneration in AD, in addition to the evidence of A deposition in a high percentage of MCI and asymptomatic healthy controls, suggests that A deposition is an early and necessary, though not sufficient, cause…”
ResultSharman, M. J., Shui, G., Fernandis, A. Z., Lim, W. L. F., Berger, T., Hone, E., Taddei, K., Martins, I. J., Ghiso, J., Buxbaum, J. D., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1348 · Cited by 35 · cited 1×
“The findings were that variations in apoE isoforms did not significantly affect bulk lipid homeostasis in the brain [46].”
BackgroundSelf-citationPupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers
Frost, S. M., Kanagasingam, Y., Sohrabi, H. R., Taddei, K., Bateman, R. J., Morris, J. C., Benzinger, T. L. S., Goate, A., Masters, C. L., & Martins, R. N. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990154 · Cited by 35 · cited 1×
“In our own studies, we have shown that pupillary reactions such as pupil flash response, can distinguish autosomal dominant AD mutation carriers from non-carriers prior to symptom appearance [143].”
BackgroundSelf-citationPedrini, S., Gupta, V. B., Hone, E., Doecke, J. D., O’Bryant, S. E., JAMES, I. R., Bush, A. I., Rowe, C. C., Villemagne, V. L., Ames, D. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14020-9 · Cited by 35
Self-citationVerdile, G., Asih, P. R., Barron, A. M., Wahjoepramono, E. J., Ittner, L. M., & Martins, R. N. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.05.020 · Cited by 34 · cited 1×
“Others have since shown that LH can influence hippocampal-related spatial memory [234], and that downregulating LH (but not estrogen therapy) can improve cognitive dysfunction and spine density loss induced by ovariectomy [235]; however, the underlying mechanisms by which these hormones influence A accumulation, metab…”
BackgroundSelf-citationLim, Y. Y., Ellis, K. A., Harrington, K., Pietrzak, R. H., Gale, J., Ames, D., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-121771 · Cited by 34 · cited 1×
“Furthermore, while memory in the cognitively unimpaired adults with low A burden (A –) remained stable over 18-months, all aspects of episodic memory were observed to deteriorate substantially in A + non-demented participants [79, 80].”
ResultSelf-citationAndrogens and Alzheimer's disease
Drummond, E., Harvey, A. R., & Martins, R. N. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832b101f · Cited by 34 · cited 1×
“Animal studies have shown benefits from testosterone supplementation in improving cognition and reducing AD pathology [225].”
BackgroundSelf-citationCerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease
Wang, F., Gordon, B. A., Ryman, D. C., Ma, S., Xiong, C., Hassenstab, J., Goate, A., Fagan, A. M., Cairns, N. J., Marcus, D. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001903 · Cited by 34
Self-citationLongitudinal cognitive decline in the AIBL cohort: The role of APOE ε4 status
Albrecht, M. A., Szoeke, C. E. I., Maruff, P. T., Savage, G. R., Lautenschlager, N. T., Ellis, K. A., Taddei, K., Martins, R. N., Masters, C. L., Ames, D. J., et al. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.06.008 · Cited by 34
Self-citationHazar, N., Seddigh, L., Rampisheh, Z., & Nojomi, M. (2016) · PubMed Central · Cited by 33
Zhang, Y., Tang, H., Peng, W., Zhang, B., & Liu, M. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.156803 · Cited by 32
Hone, E., Martins, I. J., Jeoung, M., Ji, T. H., Gandy, S. E., & Martins, R. N. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7406 · Cited by 30 · cited 1×
“In cell culture, we demonstrated that the A could influence the binding of apoE isoforms to cultured fibroblasts, such that A improved the normally poor binding of apoE 2, yet reduced the binding of apoE 3 and 4 [45].”
BackgroundSelf-citationBlair, J. A., Palm, R. F., Chang, J., McGee, H., Zhu, X., Wang, X., & Casadesús, G. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.10.013 · Cited by 30 · cited 1×
“Others have since shown that LH can influence hippocampal-related spatial memory [234], and that downregulating LH (but not estrogen therapy) can improve cognitive dysfunction and spine density loss induced by ovariectomy [235]; however, the underlying mechanisms by which these hormones influence A accumulation, metab…”
BackgroundPredicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up
Burnham, S. C., Rowe, C. C., Baker, D., Bush, A. I., Doecke, J. D., Faux, N. G., Laws, S. M., Martins, R. N., Maruff, P., Macaulay, S. L., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003094 · Cited by 30 · cited 1×
“A imaging has also been used to assess the accuracy of a panel of blood-based biomarkers in predicting brain A burden [91, 92], as well as disease progression [93].”
MethodSelf-citationHigh Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease
François, M., Fenech, M. F., Thomas, P., Hor, M., Rembach, A., Martins, R. N., Rainey‐Smith, S. R., Masters, C. L., Ames, D. J., Rowe, C. C., et al. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160315112151 · Cited by 29
Self-citationFluoro-2-Deoxy-D-Glucose (FDG)-PET in APOEε4 Carriers in the Australian Population
Rimajova, M., Lenzo, N. P., Wu, J.-S., Bates, K. A., Campbell, A., Dhaliwal, S. S., McCarthy, M., Rodrigues, M., Paton, A., Rowe, C., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13203 · Cited by 28
Self-citationGupta, V. B., Wilson, A. C., Burnham, S. C., Hone, E., Pedrini, S., Laws, S. M., Lim, W. L. F., Rembach, A., Rainey‐Smith, S. R., Ames, D. J., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0105-6 · Cited by 27
Self-citationExploring the bi-directional relationship between sleep and beta-amyloid
Brown, B. M., Rainey-Smith, S. R., Bucks, R. S., Weinborn, M., & Martins, R. N. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000285 · Cited by 27 · cited 1×
“between suboptimal sleep and AD pathology [213].”
Self-citationAsih, P. R., Chatterjee, P., Verdile, G., Gupta, V. B., Trengove, R. D., & Martins, R. N. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.29 · Cited by 25 · cited 1×
“There are several potential reasons for this: by the time AD manifests, there is already widespread damage to the brain, including considerable loss of synapses, neurons, and brain tissue, and there has been no success in trying to slow or prevent this gradually increasing pathology, after symptoms have begun [77].”
BackgroundSelf-citationAsih, P. R., Wahjoepramono, E. J., Aniwiyanti, V., Wijaya, L. K., Ruyck, K. D., Taddei, K., Fuller, S. J., Sohrabi, H. R., Dhaliwal, S. S., Verdile, G., et al. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150429112112 · Cited by 25
Self-citationPlasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study
Peters, K. E., Davis, W. A., Taddei, K., Martins, R. N., Masters, C. L., Davis, T. M. E., & Bruce, D. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161050 · Cited by 25
Self-citationMicrotubule network is required for insulin-induced signal transduction and actin remodeling
Liu, L., Cheung, S. C. K., Lan, L., Ho, S. K. S., Chan, J. C. N., & Tong, P. C. Y. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.09.005 · Cited by 24 · cited 2×
“Tau has roles in insulin transport and secretion by the pancreatic -cells [184, 185], and can also mod- ulate insulin-dependent translocation of the glucose transporter, GLUT4 [186, 187], which is critical for glucose uptake by tissues.”
Czeczor, J. K., & McGee, S. L. (2017) · Journal of Neuroendocrinology · doi:10.1111/jne.12470 · Cited by 23 · cited 1×
“The A peptide and A PP have been suggested to regulate systemic metabolism, as reviewed in [181, 182], and plasma levels of the more pathogenic A 42 are increased in T2D compared to aged matched controls [183].”
BackgroundNeuroimaging and genetic assessment for early diagnosis of Alzheimer's disease.
Gw, S. (1996) · PubMed · Cited by 22
Hou, R. H., Samuels, E. R., Raisi, M. A., Langley, R. W., Szabadi, E., & Bradshaw, C. M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0227-9 · Cited by 21 · cited 1×
“AD patients have also been found to be more sensitive to tropicamide eye drops (muscarinic cholinoceptor antagonist), thought to be due to AD-associated loss of noradrenergic neurons in the locus coeruleus [144].”
BackgroundO3‐06‐05: LONGITUDINAL COGNITIVE DECLINE IN THE AIPL COHORT: THE ROLE OF APOE ɛ4 STATUS
Foster, J. K., Albrecht, M. A., Szoeke, C. E. I., Maruff, P. T., Savage, G. R., Lautenschlager, N. T., Ellis, K. A., Taddei, K., Martins, R. N., Masters, C. L., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.303 · Cited by 21
Self-citationGardener, S. L., Rainey‐Smith, S. R., Sohrabi, H. R., Weinborn, M., Verdile, G., Fernando, W. M. A. D. B., Lim, Y. Y., Harrington, K., Burnham, S. C., Taddei, K., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161158 · Cited by 19
Self-citationNeurological soft signs are associated with APOE genotype, age and cognitive performance
Lautenschlager, N. T., Wu, J.-S., Laws, S. M., Almeida, O. P., Clarnette, R., Joesbury, K. A., Wagenpfeil, S., Martins, G., Paton, A., Gandy, S., et al. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7409 · Cited by 16 · cited 1×
“In other studies of community-dwelling volunteers, we found that neurological soft signs (abnormalities in sensory and motor performance) were associated with APOE genotype, age, and Mini-Mental State Examination (MMSE) determined cognitive performance, suggesting that such neurological soft signs may be useful in det…”
BackgroundSelf-citationNutrition between sustainability and quality.
Fara, G. M. (2016) · PubMed · doi:10.7416/ai.2015.2061 · Cited by 16
Garcia, A. A., Huang, D., Righolt, A., Righolt, C. H., Kalaw, M. C., Mathur, S., McAvoy, E., Anderson, J., Luedke, A. C., Itorralba, J., et al. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25751 · Cited by 15 · cited 1×
“ere changes [159] and DNA structural changes [163]”
BackgroundLeifert, W. R., Tuli, J. F., François, M., Nguyen, T., Rembach, A., Rumble, R. L., Rainey‐Smith, S. R., Martins, R. N., & Fenech, M. F. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150302154650 · Cited by 11 · cited 1×
“We also found in this pilot study that APOE 4 carriers trended toward lower CK14 expression [160].”
ResultSelf-citationBuccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer’s Disease Risk
Leifert, W. R., Nguyen, T., Rembach, A., Martins, R. N., Rainey‐Smith, S. R., Masters, C. L., Ames, D. J., Rowe, C. C., Macaulay, S. L., François, M., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150330 · Cited by 11
Self-citationAPOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults
Hollands, S., Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Harrington, K., Porter, T., Snyder, P. J., Ames, D. J., Fowler, C. J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161019 · Cited by 11
Self-citationModulation of Retinal Arteriolar Central Reflection by APOE Genotype
Frost, S. M., Bhuiyan, A., Offerman, D., Doecke, J. D., Macaulay, S. L., Sohrabi, H. R., Ames, D. J., Masters, C. L., Martins, R. N., Kanagasingam, Y., et al. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170309115016 · Cited by 11
Self-citationQuantitative 3D Telomeric Imaging of Buccal Cells Reveals Alzheimer’s Disease-Specific Signatures
Garcia, A. A., Mathur, S., Kalaw, M. C., McAvoy, E., Anderson, J. A., Luedke, A. C., Itorralba, J., & Mai, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161169 · Cited by 11 · cited 2×
“ere changes [159] and DNA structural changes [163]”
BackgroundAlzheimer's disease: a current review.
Wj, W., & Hs, S. (1984) · PubMed Central · Cited by 5
The Australian Biomarkers Lifestyle and Imaging flagship study of ageing
Ellis, K. A., Ames, D. J., Martins, R. N., Hudson, P. J., & Masters, C. L. (2006) · Acta Neuropsychiatrica · doi:10.1017/s0924270800031136 · Cited by 5
Self-citation
Research works printed but not linked: 8
- Hazar N, 2016, Iran J Neurol, 15, 164
- Watson WJ, 1984, Can Fam Physician, 30, 595
- Small GW, 1996, J Clin Psychiatry, 57, 9
- Ellis K, 2006, Acta Neuropsychiatr, 18, 285
- Fara GM, 2015, Ann Ig, 27, 693
- An Y, 2017, Alzheimers Dement
- Shi L, 2017, Sleep Med Rev
- Wang YQ, 2016, Eur Rev Med Pharmacol Sci, 20, 2389
Cited by
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Understanding mechanisms of antioxidant action in health and disease
Halliwell, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 629
“For example, vitamin E inhibits lipid peroxidation but may not prevent the increased oxidative DNA, RNA and protein damage seen in Alzheimer disease 123,156–159 .”
Zucchella, C., Sinforiani, E., Tamburin, S., Federico, A., Mantovani, E., Bernini, S., Casale, R., & Bartolo, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01058 · Cited by 297
Metadata
- Authors
- Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., Hone, E., Pedrini, S., Lim, W. L., Martins, I., Frost, S., Gupta, S., O’Bryant, S., Rembach, A., Ames, D., Ellis, K., Fuller, S. J., Brown, B., Gardener, S. L., Fernando, B., Bharadwaj, P., Burnham, S., Laws, S. M., Barron, A. M., Goozee, K., Wahjoepramono, E. J., Asih, P. R., Doecke, J. D., Salvado, O., Bush, A. I., Rowe, C. C., Gandy, S. E., & Masters, C. L.
- Affiliations
- Edith Cowan University (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- University of Toronto (CA)
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Commonwealth Scientific and Industrial Research Organisation (AU)
- University of North Texas (US)
- The University of Melbourne (AU)
- Australian Alzheimer’s Research Foundation (AU)
- Murdoch University (AU)
- Nanyang Technological University (SG)
- The University of Western Australia (AU)
- UNSW Sydney (AU)
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Cooperative Research Centre for Mental Health (AU)
- Corresponding author
- Martins, Ralph N.
- ORCID
- Martins, Ralph N.
- Villemagne, Victor
- Sohrabi, Hamid R.
- Chatterjee, Pratishtha
- Shah, Tejal M.
- Verdile, Giuseppe
- Fraser, Paul
- Taddei, Kevin
- Gupta, Veer B.
- Hone, Eugene
- Pedrini, Steve
- Lim, Wei Ling
- Martins, Ian
- Frost, Shaun
- O’Bryant, Sid
- Ellis, Kathryn
- Brown, Belinda
- Gardener, Samantha L.
- Burnham, Samantha
- Laws, Simon M.
- Barron, Anna M.
- Goozee, Kathryn
- Wahjoepramono, Eka J.
- Asih, Prita R.
- Doecke, James D.
- Salvado, Olivier
- Bush, Ashley I.
- Rowe, Christopher C.
- Masters, Colin L.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-03-13
- Volume
- 62
- Issue
- 3
- Pages
- 965-992
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5870031
- OpenAlex
- W2794133158
- Cited by
- 129
- References
- 239
- Citations by year
- 2026: 1 · 2025: 14 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 23 · 2019: 13 · 2018: 3
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc)
- Murdoch University Research Portal (submittedVersion)
- Australasian Journal of Paramedicine (submittedVersion, cc-by-nc)
- Deakin Research Online (Deakin University) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Australia, Humans, Biomarkers, Oxidative Stress, Amyloidogenic Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.